Rest Therapeutics
Last verified 2026-05-08. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $5.0Mattributed |
|---|---|
| Latest round | grant, $2.7M, 2023-07-01attributed |
| Founded | 2020 |
| Headquarters | Montpellier, France |
| Industry | biotech |
| Stage | unknown |
| Website | rest-therapeutics.com |
ReST Therapeutics develops FENM, a small molecule that modulates NMDA-receptor activity to treat central nervous system disorders such as PTSD and Alzheimer's. It targets patients with neurodegenerative and stress-related conditions. Its NMDA-subtype modulation aims to halt disease progression, not just relieve symptoms.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2023-07-01 | grant | $2.7M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Grant, $2.7M | attributed | eu-grant named as publisher. No document URL on file. |
| Total raised $5.0M | attributed | eu-grant named as publisher. No document URL on file. |
| Company existence | self-reported | rest-therapeutics.com, read 2026-05-08 |
| Description | self-reported | rest-therapeutics.com, read 2026-05-08 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.